SCYNEXIS Inc.

04/27/2022 | Press release | Distributed by Public on 04/27/2022 06:33

SCYNEXIS Presents Data Analyses Showing Ibrexafungerp’s Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd[...]

  • New interim analysis of the Phase 3 CARES study showed complete or partial response in 78% of the 18 patients treated with ibrexafungerp for infections caused by Candida auris, a potentially deadly and multidrug-resistent pathogen with an outbreak recently reported at a Detroit specialty hospital.1

  • Interim data of the ongoing Phase 3 FURI and CARES studies of patients with invasive candidiasis and candidemia treated with ibrexafungerp is positive and consistent with previous analyses.

  • Additional new in vivo data presented supports ibrexafungerp as a potential treatment for mucormycosis, a debilitating and sometimes deadly fungal infection that has seen an increase in cases globally during the COVID-19 pandemic.